MTR4 study links a protein to vascular aging in cells and animals

Blood vessels do more than carry blood: the endothelial cells lining them regulate inflammation, blood flow, tissue repair and the movement of cells and nutrients between circulation and organs. Those powers begin to fray with age. Senescent endothelial cells stop dividing, release inflammatory molecules and damage surrounding tissue, helping drive vascular disease and the decline of multiple organs. A new study identifies MTR4, an RNA-processing protein long known for helping cells control nuclear RNA, as a previously unrecognized guardian of vascular youth. Restoring MTR4 in the endothelium of aged mice improved vascular function, reduced senescence and inflammation across major organs, and reversed several features of aging, while increasing the same protein extended the lifespan of the nematode Caenorhabditis elegans.

The work, reported in Aging Cell, suggests that aging does not simply switch off genes that protect cells. It can actively dismantle their protein products. MTR4, also known as SKIV2L2, is an evolutionarily conserved helicase and core partner of the nuclear RNA exosome, a machinery that processes and degrades RNA. The researchers found that MTR4 protein declined as human umbilical vein endothelial cells entered senescence through serial passage, oxidative stress or DNA damage. The same loss appeared in aortas from aged mice, while analysis of a single-cell mouse atlas showed lower Mtr4 expression specifically in endothelial cells carrying the strongest senescence signature. Importantly, Mtr4 did not fall merely because cells stopped dividing: its levels remained stable in quiescent, contact-inhibited endothelial cells, indicating a link to senescence rather than a generic response to cell-cycle arrest.

Cultured human endothelial cells established that MTR4 is not simply a passenger in the aging process. Depleting MTR4 increased senescence-associated beta-galactosidase staining and raised the levels of p16, p21, p53 and gamma-H2A.X, a marker of DNA damage. It also reduced endothelial nitric oxide synthase, an enzyme important for vascular function, and increased messenger RNA for a broad inflammatory secretome, including IL-1, IL-6, CCL2, TGF-beta, MMP3 and TNF-alpha. The effect was reversible: introducing MTR4 into already senescent cells lowered senescence markers, preserved endothelial nitric oxide synthase and suppressed the inflammatory molecules. These complementary experiments place MTR4 on the functional side of the balance, where maintaining it reduces senescence and restoring it partially reverses the phenotype.

Protein-interaction screening revealed the molecular link. Mass spectrometry identified 92 proteins associated with MTR4, and five of them also appeared in a database of aging-related genes. Follow-up experiments confirmed direct binding between MTR4 and two candidates, BUB3 and FEN1, but rescue tests distinguished them: restoring BUB3 reduced senescence markers in MTR4-depleted cells, whereas FEN1 did not. MTR4 used a structural region called the rRNA pro-arch domain to bind BUB3. A version of MTR4 lacking this domain could still catalyze RNA processing but failed to capture BUB3 or rescue senescence, showing that the physical partnership, not merely the enzyme’s catalytic activity, is essential.

The mechanism downstream of that partnership involves protein stability and genome surveillance. Blocking new RNA synthesis with actinomycin D did not explain the effect of MTR4 depletion on BUB3, but blocking protein translation with cycloheximide did: BUB3 disappeared faster in cells lacking MTR4. MTR4 therefore stabilizes BUB3 at the protein level. BUB3, in turn, supports the stability of BUBR1, a kinase central to the spindle assembly checkpoint that monitors chromosome attachment before cell division. MTR4 depletion lowered BUBR1 and increased DNA damage, while BUB3 replacement restored the checkpoint protein and reduced the senescence signal. The findings connect an RNA helicase to chromosome segregation, DNA integrity and the decision to remain proliferative or enter senescence, although the precise way MTR4 physically stabilizes BUB3 remains unknown.

The study also identified why MTR4 disappears as endothelial cells age. Its messenger RNA did not decline in senescent human cells or aged mouse aortas, pointing to a post-transcriptional mechanism. Blocking the proteasome stabilized MTR4, whereas several autophagy inhibitors did not, and MTR4 extracted from senescent cells carried more ubiquitin than protein from proliferating cells. Mass spectrometry and mutational analysis localized the modification to lysine 638, or K638, within the same rRNA pro-arch domain used to bind BUB3. This residue is conserved from humans to pigs. The E3 ubiquitin ligase SYVN1, whose levels rise during senescence, increased ubiquitination at K638 and drove MTR4 toward degradation. Blocking SYVN1 restored MTR4, and an engineered K638-to-arginine mutant that resisted this modification reversed senescence markers as effectively as ordinary MTR4 in senescent cells.

Mice provided evidence that the pathway matters in a living vascular system. Endothelial Mtr4 knockdown in young animals impaired exploratory behavior, changed aortic blood-flow velocity, narrowed abdominal aortic dimensions, raised p16, p21 and p53 in the aorta, and increased circulating IL-1 beta and IL-6. It also produced senescence-associated staining in the aorta, liver, lung and kidney. Histology showed aging-like changes including liver-cell vacuolization, enlarged lung spaces, irregular splenic structure and glomerulosclerosis. Conversely, endothelium-specific Mtr4 overexpression in aged mice improved exploratory behavior and vascular measurements, reduced senescence markers and inflammatory cytokines, and brought organ morphology closer to that of young controls. Body weight did not differ significantly in these experiments. The work did not establish whether MTR4 can extend mammalian lifespan.

The strongest longevity result came from worms. Researchers reduced expression of the MTR4 homolog mtr-4 with RNA interference and observed shorter lifespan, reduced pharyngeal pumping and body bending, less spontaneous movement, increased lipofuscin and lipid accumulation, poorer resistance to heat and oxidative stress, and elevated reactive oxygen species. Transgenic worms that overexpressed mtr-4 displayed the opposite pattern. They lived longer, remained more active, accumulated less age-associated pigment and fat, tolerated stress better and had lower basal reactive oxygen species. The researchers report that mtr-4 overexpression produced a lifespan increase comparable to canonical longevity mutants, including the dietary-restriction model eat-2. That remarkable effect remains a finding in worms rather than proof of a longevity treatment for people.

For medicine, the most immediate implication is that preserving a healthy endothelial state may require more than removing senescent cells or suppressing their inflammatory secretions. Such broad strategies can disrupt barrier integrity, wound healing, immune surveillance or tissue repair. Strengthening an intrinsic protective pathway may offer a narrower alternative, and MTR4 appears to provide one: it supports BUB3, preserves BUBR1, limits DNA damage and helps maintain vascular function. The study nevertheless remains preclinical. Its treatments used gene manipulation in cells, worms and mice, not an approved therapy, and the researchers did not test whether MTR4 is depleted in older or atherosclerotic human patients. Questions also remain about whether it influences diabetic vasculopathy, atherosclerosis or human lifespan. Even so, the convergence across human endothelial cells, mice and worms identifies a striking new principle: youthful blood vessels may depend not only on preventing damage, but on continuously preserving a specific RNA-processing protein that keeps their genome and cell-cycle machinery in working order.

Subject of Research: MTR4 regulation of endothelial senescence, vascular aging and organismal longevity

Article Title: MTR4: A Conserved Youth Factor for Vascular Endothelium

Article References: Guo, Z., Chen, Z., Sun, J., Zhou, X., Ni, C., Zhang, Y., Qiang, P., & Zhang, L. (2026). MTR4 : A Conserved Youth Factor for Vascular Endothelium. Aging Cell, 25(10), Article e70774. https://doi.org/10.1111/acel.70774

Image Credits: AI Generated

DOI: 10.1111/acel.70774

Keywords: MTR4, vascular aging, endothelial senescence, BUB3, SYVN1, RNA helicase, gene therapy, mouse aging, C. elegans, longevity, Conserved, Youth